Dr Mark Sidhom

Dr Mark Sidhom

Dr Mark Sidhom
B.Ec. LL.B. MBBS FRANZCR, Radiation Oncologist

Languages spoken




Campbelltown (Oncology)
Campbelltown (Oncology)

38 Camden Road, Campbelltown NSW 2560

-34.071101399509224, 150.80602556751086

Clinical interest in genitourinary cancers (including prostate, bladder and kidney cancer).

Dr Mark Sidhom is committed to offering modern precision radiotherapy to his patients so as with the aim to achieve the best possible clinical outcomes, while minimising the risk of side effects.

Mark completed a Bachelor of Economics and a Bachelor of Law with first class honours prior to graduating from a Bachelor of Medicine from the University of Sydney in 2001. He trained in Queensland and New South Wales, completing his advanced training in radiation oncology in 2008. Mark was awarded the FRANZCR College medal for being the top ranked radiation oncologist in the fellowship exams.

Mark’s key clinical interest is in the management of genitourinary malignancies (including prostate, bladder and kidney cancers) with over 15 years’ experience as a radiation oncologist in the field, utilising a range of advanced techniques, such as delivering a combination of radiation therapy and chemotherapy as a treatment option offered to appropriate bladder cancer patients – thereby aiming to avoid bladder removal.  

Mark has been extensively involved in research over the last 15 years with greater than 50 publications in peer reviewed journals, as well as presentations both in Australia and internationally. He is a regular speaker at national and international scientific meetings. Mark is involved in a number of national prostate, bladder and kidney cancer co-operative groups and research bodies, being an executive member of the Faculty of Radiation Oncology Genitourinary Group since 2010 (FROGG), and is an active recruiter to clinical trials of the Trans-Tasman Radiation Oncology Group (TROG). Mark is a co-chair of the multicentre TROG 18.01 NINJA trial investigating the optimum stereotactic radiotherapy regimen for men with intermediate and high-risk prostate cancer.

On weekends Mark is an enthusiastic road cyclist, competing in ultra-endurance cycling events around Australia.